|
|
Volumn 16, Issue 3, 2017, Pages 157-
|
|
Trial watch: Clinical trial cycle times continue to increase despite industry efforts
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
MONOCLONAL ANTIBODY;
BENCHMARKING;
CLINICAL STUDY;
CLINICAL TRIAL (TOPIC);
CLINICAL TRIAL CYCLE TIME;
DRUG INDUSTRY;
DRUG MANUFACTURE;
DRUG MARKETING;
HUMAN;
METHODOLOGY;
NOTE;
PEER GROUP;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PROCESS CONTROL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RESEARCH SUBJECT;
STATISTICAL ANALYSIS;
TOTAL QUALITY MANAGEMENT;
TREATMENT DURATION;
DRUG DEVELOPMENT;
ORGANIZATION AND MANAGEMENT;
PROCEDURES;
TIME FACTOR;
TRENDS;
CLINICAL TRIALS AS TOPIC;
DRUG DISCOVERY;
DRUG INDUSTRY;
TIME FACTORS;
|
|
EID: 85011835406
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd.2017.21 Document Type: Note |
|
Times cited : (40)
|
|
References (0)
|
